GlassScriptPhysician profile
Mostafa Aboubakr
NPI 1841713427
$6,318.25
in general payments reported to CMS, 2019-2025
32 companies · $1,480 in 2025
The $1,480 reported for 2025 was more than what 83% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
See the full distribution for Critical Care Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $366 · 2020: $121 · 2022: $36.45 · 2023: $350 · 2024: $3,964 · 2025: $1,480.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,015 · Education: $2,517 · Travel and Lodging: $262.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,015.31 |
| Education | $2,517.38 |
| Travel and Lodging | $262.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $2,762.23 | 2024 | |
| Genzyme Corporation | $678.79 | 2024-2025 | |
| Astrazeneca Pharmaceuticals LP | $459.93 | 2023-2025 | Tezspire, Fasenra, Breztri |
| Glaxosmithkline, LLC. | $302.02 | 2022-2025 | Trelegy Ellipta, Arexvy |
| Grifols USA, LLC | $239.12 | 2024-2025 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $159.16 | 2023-2025 | Ofev |
| Sanofi-Aventis U.S. LLC | $124.01 | 2019 | |
| Gilead Sciences, INC. | $121.75 | 2019 | |
| Amgen INC. | $121.18 | 2020 | |
| Edwards Lifesciences Corporation | $119.94 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $97.79 | 2023-2025 | Uptravi, Opsynvi, Opsumit |
| Insmed, INC. | $94.57 | 2025 | Arikayce |
| Ucb, INC. | $93.12 | 2023-2024 | Briviact |
| Merck Sharp & Dohme LLC | $91.33 | 2023-2025 | Zerbaxa, Winrevair, Recarbrio |
| Electromed, INC. | $88.58 | 2024-2025 | Smartvest |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viatris Specialty LLC | $87.72 | 2025 | Yupelri |
| Pfizer INC. | $76.61 | 2023-2025 | |
| Baxter Healthcare | $76.02 | 2024-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Abbvie INC. | $73.80 | 2025 | |
| Verona Pharma, INC. | $68.00 | 2025 | Ohtuvayre |
| Ani Pharmaceuticals, INC. | $60.64 | 2025 | Purified Cortrophin Gel |
| La Jolla Pharmaceutical Company | $59.96 | 2024 | Giapreza |
| Janssen Pharmaceuticals, INC | $41.34 | 2023 | Xarelto |
| Abiomed | $38.01 | 2024 | Impella |
| Inogen, INC. | $32.87 | 2023-2024 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Paratek Pharmaceuticals, INC. | $32.48 | 2023 | Nuzyra |
| Vifor Pharma, INC. | $27.92 | 2024 | Zemaira |
| Mylan Specialty L.P. | $20.45 | 2024 | Yupelri |
| Scpharmaceuticals INC. | $19.47 | 2025 | |
| Alexion Pharmaceuticals, INC. | $17.42 | 2024 | Ultomiris |
| Shionogi INC | $16.67 | 2024 | Fetroja |
| Philips North America LLC | $15.35 | 2025 | Vest Therapy Und |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mostafa Aboubakr listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.